EBS
Emergent BioSolutionsCNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
Current thesis
The cleanest bullish datapoint is the Q1 beat versus consensus cited by secondary earnings trackers: adjusted EPS of $0.21 versus a -$0.25 estimate and revenue of $156.1M versus about $145M, alongside maintained FY revenue guidance of $720M-$760M and revised adjusted EBITDA guidance of $155M-$175M after the non-cash stock-comp add-back. If quarterly execution stabilizes, the $8.95 anchor leaves room toward the packet's $13.5 median target, but the weak peer set and limited revision evidence keep this a tentative setup.
Posture
Mixed
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.1.
What can break
Government procurement timing still drives large swings in anthrax and smallpox medical-countermeasure revenue.
Momentum
11
Value
72
Sentiment
67
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $9.50 · Bull $12.50 · Bear $6.00
Data freshness
Prices
As of 2026-07-21
Fundamentals
As of 2026-07-21 • Vendor: Data Vendor v1
Scores
As of 2026-07-21 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-12 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-21
Investment thesis
As of 2026-07-21
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $12.00
Why
Momentum11 · Δ7d -9.3
Value72 · Δ7d +0.1
Sentiment67 · Δ7d +0.6
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Value · See fundamentals
Momentum
11
26% active weight
Current posture
7d trendSoftening
Δ7d
-9.3
Δ21d
-6.7
Value
72
39% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.1
Sentiment
67
34% active weight
Current posture
7d trendFlat
Δ7d
+0.6
Δ21d
+6.3
Why this grade
Composite grade C. Momentum 11.4 / Value 72.1 / Sentiment 67.4
Fundamentals (TTM)As of 2026-07-21
Fundamentals (TTM)
As of 2026-07-21
Market Cap
$394.71M
Beta
2.35
Shares Out
51.6M
P/E (TTM)
9.9
P/S (TTM)
0.86
P/FCF (TTM)
482.06
Rev YoY
-29.7%
EPS YoY
-93.7%
Gross Margin
+44.4%
Op Margin
+15.2%
Net Debt
$374.6M
Current Ratio
4.29
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology